Risk prediction of drug-drug interaction potential of phenytoin and miconazole topical formulations.

[1]  Francesco Brigo,et al.  Management of status epilepticus in adults. Position paper of the Italian League against Epilepsy , 2019, Epilepsy & Behavior.

[2]  Chunzhi Ai,et al.  The association between CYP2C9/2C19 polymorphisms and phenytoin maintenance doses in Asian epileptic patients: A systematic review and meta-analysis
. , 2018, International journal of clinical pharmacology and therapeutics.

[3]  S. Iwasaki,et al.  Unbound liver concentration is the true inhibitor concentration that determines cytochrome P450-mediated drug–drug interactions in rat liver , 2017, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  E. Hak,et al.  Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6. , 2017, Pharmacogenomics.

[5]  J. Hallas,et al.  Topical Antimycotics for Oral Candidiasis in Warfarin Users , 2017, Basic & clinical pharmacology & toxicology.

[6]  E. Perucca,et al.  CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects , 2015, Expert opinion on drug metabolism & toxicology.

[7]  Yong Liu,et al.  Inhibition of SN-38 glucuronidation by gefitinib and its metabolite , 2015, Cancer Chemotherapy and Pharmacology.

[8]  F. Tas,et al.  Combination of capecitabine and phenytoin may cause phenytoin intoxication: a case report. , 2015, American journal of therapeutics.

[9]  H. Yamazaki,et al.  Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450. , 2015, Current drug metabolism.

[10]  Y. Daali,et al.  Applications of CYP450 Testing in the Clinical Setting , 2013, Molecular Diagnosis & Therapy.

[11]  J. Lindh,et al.  A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele. , 2012, Pharmacogenomics.

[12]  K. Yamagata,et al.  Interaction of miconazole oral gel with warfarin and cyclosporine in a patient with nephrotic syndrome , 2012, CEN Case Reports.

[13]  T. Manjari,et al.  Genetic Polymorphism of NAT2 Metabolizing Enzymes on Phenytoin Pharmacokinetics in Indian Epileptic Patients Developing Toxicity , 2012, CNS neuroscience & therapeutics.

[14]  R. N. Brogden,et al.  Miconazole: A Preliminary Review of its Therapeutic Efficacy in Systemic Fungal Infections , 2012, Drugs.

[15]  J. Meer,et al.  The Influence of NSAIDs on Coumarin Sensitivity in Patients with CYP2C9 Polymorphism After Total Hip Replacement Surgery , 2012, Molecular Diagnosis & Therapy.

[16]  Y. Sawada,et al.  Warfarin and miconazole oral gel interactions: analysis and therapy recommendations based on clinical data and a pharmacokinetic model , 2011, Journal of clinical pharmacy and therapeutics.

[17]  P. Neuvonen,et al.  Miconazole Oral Gel Increases Exposure to Oral Oxycodone by Inhibition of CYP2D6 and CYP3A4 , 2010, Antimicrobial Agents and Chemotherapy.

[18]  F. Nielsen,et al.  Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women , 2010, European Journal of Clinical Pharmacology.

[19]  M. Ratain,et al.  Comparison of the Drug-Drug Interactions Potential of Erlotinib and Gefitinib via Inhibition of UDP-Glucuronosyltransferases , 2010, Drug Metabolism and Disposition.

[20]  Yong Liu,et al.  UDP-Glucuronosyltransferase 1A6 Is the Major Isozyme Responsible for Protocatechuic Aldehyde Glucuronidation in Human Liver Microsomes , 2008, Drug Metabolism and Disposition.

[21]  A. Barasch,et al.  Miconazole revisited: new evidence of antifungal efficacy from laboratory and clinical trials. , 2008, Future microbiology.

[22]  P. Neuvonen,et al.  Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib , 2008, European Journal of Clinical Pharmacology.

[23]  Ling Yang,et al.  Inhibitory effect of medroxyprogesterone acetate on human liver cytochrome P450 enzymes , 2006, European Journal of Clinical Pharmacology.

[24]  A. Takagi,et al.  [Drug-drug interaction of antifungal drugs]. , 2005, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[25]  A. Hofman,et al.  Allelic Variants of Cytochrome P450 2C9 Modify the Interaction Between Nonsteroidal Anti‐inflammatory Drugs and Coumarin Anticoagulants , 2005, Clinical pharmacology and therapeutics.

[26]  C. Dubray,et al.  Comparison of the pharmacokinetics of miconazole after administration via a bioadhesive slow release tablet and an oral gel to healthy male and female subjects. , 2004, British journal of clinical pharmacology.

[27]  M. Pemberton,et al.  Miconazole oral gel and drug interactions , 2004, British Dental Journal.

[28]  V. Schuermans,et al.  Systemic antifungal potential, safety, biotransport and transformation of micronazole nitrate , 1972, European Journal of Clinical Pharmacology.

[29]  P. Desai,et al.  Bioavailability Study of a 1200 mg Miconazole Nitrate Vaginal Ovule in Healthy Female Adults , 2002, Journal of clinical pharmacology.

[30]  T. R. Brodribb,et al.  Phenytoin and Fluorouracil Interaction , 2001, The Annals of pharmacotherapy.

[31]  A. Wood,et al.  Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo. , 2001, Pharmacogenetics.

[32]  Y. Sugiyama,et al.  Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. , 1998, Annual review of pharmacology and toxicology.

[33]  K. Coley,et al.  Miconazole‐Induced Fatal Dysrhythmia , 1997, Pharmacotherapy.

[34]  T. Tamaya,et al.  Pharmacokinetics of miconazole in serum and exudate of pelvic retroperitoneal space after radical hysterectomy and pelvic lymphadenectomy. , 1997, International journal of antimicrobial agents.

[35]  T. Daneshmend.  Systemic absorption of miconazole from the vagina. , 1986, The Journal of antimicrobial chemotherapy.

[36]  A. Somogyi,et al.  Phenytoin intoxication during treatment with parenteral miconazole. , 1983, British medical journal.

[37]  R. Mäntylä,et al.  Impairing effect of food on ketoconazole absorption , 1982, Antimicrobial Agents and Chemotherapy.

[38]  P. Neuvonen.  Bioavailability of Phenytoin: Clinical Pharmacokinetic and Therapeutic Implications , 1979, Clinical pharmacokinetics.

[39]  A. Richens,et al.  Effect of age, height, weight and sex on serum phenytoin concentration in epileptic patients. , 1975, British journal of clinical pharmacology.

[40]  A. Richens,et al.  Rate of elimination of tracer doses of phenytoin at different steady-state serum phenytoin concentrations in epileptic patients. , 1974, British journal of clinical pharmacology.